Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward
Year: 2016
Type: article
Abstract: The field of Alzheimer disease (AD) prevention has been a culmination of basic science, clinical, and translational research. In the past three years since the new 2011 AD diagnostic guidelines, large-scale collaborative efforts have embarked on new clinical trials with the hope of someday preventing AD. This review will shed light on the historical and scientific contexts in which these trials were based on, as well as discuss potential challenges these trials may face in the coming years. Primary preventive measures, such as lifestyle, multidomain, medication, and supplemental interventions, will be analyzed. Secondary prevention as represented by disease-modifying interventions, such as antiamyloid therapy and pioglitazone, will also be reviewed. Finally, hypotheses on future directions for AD prevention trials will be proposed.
Source: Current Alzheimer Research
Authors: David Hsu, Gad A. Marshall
Institutions: Brigham and Women's Hospital, Harvard University
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
Awards: Mentoring Imaging Research in Early AD, Evolution of memory related fMRI activation over the course of MCI and AD, Characterizing the Evolution of Amyloid Deposition in Normal Elderly, Massachusetts Alzheimer's Disease Research Center, PIB binding, hypometabolism, apathy and executive dysfunction in MCI and AD, Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study
OpenAlex ID: W2539113442
